文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

亚铁螯合肽激动剂作为治疗工具。

Hepcidin agonists as therapeutic tools.

机构信息

Division of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA; and.

Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.

出版信息

Blood. 2018 Apr 19;131(16):1790-1794. doi: 10.1182/blood-2017-11-737411. Epub 2018 Mar 9.

DOI:10.1182/blood-2017-11-737411
PMID:29523504
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5909761/
Abstract

Hepcidin agonists are a new class of compounds that regulate blood iron levels, limit iron absorption, and could improve the treatment of hemochromatosis, β-thalassemia, polycythemia vera, and other disorders in which disrupted iron homeostasis causes or contributes to disease. Hepcidin agonists also have the potential to prevent severe complications of siderophilic infections in patients with iron overload or chronic liver disease. This review highlights the preclinical studies that support the development of hepcidin agonists for the treatment of these disorders.

摘要

亚铁整合素激动剂是一类新的化合物，可调节血液中铁的水平，限制铁的吸收，并可能改善血色病、β-地中海贫血、真性红细胞增多症和其他铁稳态失调导致或促成疾病的疾病的治疗。亚铁整合素激动剂还有可能预防铁过载或慢性肝病患者中噬铁菌感染的严重并发症。本综述强调了支持开发亚铁整合素激动剂治疗这些疾病的临床前研究。

相似文献

[1]
Hepcidin agonists as therapeutic tools.

Blood. 2018-3-9

[2]
New thiazolidinones reduce iron overload in mouse models of hereditary hemochromatosis and β-thalassemia.

Haematologica. 2019-2-21

[3]
Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera.

Blood. 2016-7-14

[4]
A competitive enzyme-linked immunosorbent assay specific for murine hepcidin-1: correlation with hepatic mRNA expression in established and novel models of dysregulated iron homeostasis.

Haematologica. 2015-2

[5]
Liver iron concentrations and urinary hepcidin in beta-thalassemia.

Haematologica. 2007-5

[6]
Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches.

Hematol Oncol Clin North Am. 2014-4

[7]
Hepcidin biology and therapeutic applications.

Expert Rev Hematol. 2010-4

[8]
Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice.

J Clin Invest. 2010-11-22

[9]
The pathophysiology and pharmacology of hepcidin.

Trends Pharmacol Sci. 2014-2-17

[10]
Hepcidin-induced hypoferremia is a critical host defense mechanism against the siderophilic bacterium Vibrio vulnificus.

Cell Host Microbe. 2015-1-14

引用本文的文献

[1]
A TMPRSS6-inhibiting mAb improves disease in a β-thalassemia mouse model and reduces iron in healthy humans.

JCI Insight. 2025-6-23

[2]
Polycythaemia vera.

Nat Rev Dis Primers. 2025-4-17

[3]
Hepcidin mediates the disorder of iron homeostasis and mitochondrial function in mice under hypobaric hypoxia exposure.

Apoptosis. 2025-4

[4]
Cardiac injury caused by iron overload in thalassemia.

Front Pediatr. 2025-1-27

[5]
Hepcidin Is a Valuable Therapeutic Target for Colorectal Cancer.

Cancers (Basel). 2024-12-5

[6]
Pharmacokinetics and Pharmacodynamics of Rusfertide, a Hepcidin Mimetic, Following Subcutaneous Administration of a Lyophilized Powder Formulation in Healthy Volunteers.

Drugs R D. 2024-12

[7]
Bile from the hemojuvelin-deficient mouse model of iron excess is enriched in iron and ferritin.

Metallomics. 2024-10-4

[8]
Exploring the bone marrow micro environment in thalassemia patients: potential therapeutic alternatives.

Front Immunol. 2024

[9]
Association of iron overload with infectious complications in liver transplant recipients: a systematic review and meta-analysis.

J Int Med Res. 2024-3

[10]
A Review of New Concepts in Iron Overload.

Gastroenterol Hepatol (N Y). 2024-2

本文引用的文献

[1]
What can we learn from ineffective erythropoiesis in thalassemia?

Blood Rev. 2017-10-3

[2]
Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing non-transferrin-bound iron.

Blood. 2017-7-20

[3]
Hepcidin-mediated iron sequestration protects against bacterial dissemination during pneumonia.

JCI Insight. 2017-3-23

[4]
Targeting iron metabolism in drug discovery and delivery.

Nat Rev Drug Discov. 2017-6

[5]
A Red Carpet for Iron Metabolism.

Cell. 2017-1-26

[6]
Pharmacological Targeting of the Hepcidin/Ferroportin Axis.

Front Pharmacol. 2016-6-21

[7]
Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera.

Blood. 2016-7-14

[8]
Haemochromatosis.

Lancet. 2016-3-12

[9]
New strategies to target iron metabolism for the treatment of beta thalassemia.

Ann N Y Acad Sci. 2016-3

[10]
Hepcidin regulation in the anemia of inflammation.

Curr Opin Hematol. 2016-5

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索